Novikov PI, et al. - Authors reported the effectiveness and safety of certolizumab pegol (CZP) in a case series of patients with refractory Takayasu arteritis (TA). They treated 10 females of reproductive age (18–35 years) having TA with CZP (at a dose of 400 mg at weeks 0, 2 and 4 and at 200 mg every 2 weeks thereafter) for a median of 10 months (range 3–28). Findings suggested the effectiveness of CZP in patients with active TA. This treatment was seen to be steroid-sparing in these patients even if they did not respond to other TNF inhibitors or tocilizumab previously. Mild infections were included in the side effects.